•
Sep 30, 2024

DaVita Q3 2024 Earnings Report

DaVita's Q3 2024 financial performance was solid, with a focus on providing quality care and resilience in the face of severe storms.

Key Takeaways

DaVita Inc. reported consolidated revenues of $3.264 billion and an operating income of $535 million for the third quarter of 2024. Diluted earnings per share was $2.50, and adjusted diluted earnings per share was $2.59. The company repurchased 2.7 million shares of its common stock at an average price of $147.20 per share.

Consolidated revenues reached $3.264 billion.

Operating income totaled $535 million.

Diluted EPS was $2.50, and adjusted diluted EPS was $2.59.

The company repurchased 2.7 million shares for $406 million.

Total Revenue
$3.26B
Previous year: $3.12B
+4.6%
EPS
$2.59
Previous year: $2.85
-9.1%
US Dialysis Treatments
7.35M
Previous year: 7.31M
+0.6%
US Avg Treatments per day
93.05K
Previous year: 92.49K
+0.6%
US Revenue per Treatment
$394
Previous year: $380
+3.7%
Gross Profit
$1.11B
Previous year: $1.05B
+5.5%
Cash and Equivalents
$1.07B
Previous year: $449M
+138.2%
Free Cash Flow
$555M
Previous year: $453M
+22.5%
Total Assets
$17.5B
Previous year: $16.9B
+3.4%

DaVita

DaVita

DaVita Revenue by Segment

DaVita Revenue by Geographic Location

Forward Guidance

DaVita provided its 2024 guidance, which no longer excludes center closure costs.

Positive Outlook

  • Adjusted operating income is expected to be between $1.91 billion and $2.01 billion.
  • Adjusted diluted net income per share is projected to be between $9.25 and $10.05.
  • Free cash flow is anticipated to range from $950 million to $1.2 billion.

Revenue & Expenses

Visualization of income flow from segment revenue to net income